An innovative outcome-based care and procurement model of hemophilia management

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 16, Issue 3, 2016, Pages 337-345

  Gringeri, Alessandro ^a   Doralt, Jennifer ^a   Valentino, Leonard A ^b,c   Crea, Roberto ^a   Reininger, Armin J ^a  

^a Baxalta Innovations GmbH   (Austria)

^b Baxalta US   (United States)

^c RUSH UNIVERSITY   (United States)

Author keywords

hemophilia; patient centered care; personalized therapy; procurement model; Prophylaxis; tailored care

Indexed keywords

ABSENTEEISM; ARTHROPATHY; ARTICLE; BLEEDING; CHRONIC PAIN; COST CONTROL; DISEASE ASSOCIATION; HEALTH CARE; HEALTH CARE QUALITY; HEALTH PROGRAM; HEMOPHILIA; HOLISTIC CARE; HUMAN; INNOVATIVE OUTCOME BASED CARE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHYSICAL MOBILITY; SCHOOL ATTENDANCE; SELF CARE; TREATMENT OUTCOME; BUDGET; ECONOMICS; HEMOPHILIA A; HEMORRHAGE; PATHOPHYSIOLOGY; PHILOSOPHY; PROCEDURES; THEORETICAL MODEL;

BUDGETS; HEMOPHILIA A; HEMORRHAGE; HOLISTIC HEALTH; HUMANS; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); PRECISION MEDICINE; SELF CARE;

EID: 84965082636     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1080/14737167.2016.1178066     Document Type: Article

References (80)

1. P.M.Mannucci, E.G.D.Tuddenham The hemophilias: progress and problems. Semin Hematol. 1999;36:104–117.
2. A.Srivastava, A.K.Brewer, E.P.Mauser-Bunschoten, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1–e47.
3. L.A.Valentino. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost. 2010;8:1895–1902.
4. J.Oldenburg. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125:2038–2044.• This paper stresses the importance of considering many individual factors (patient-tailored care) when utilizing resources to treat hemophilia, including physical activity levels, pharmacokinetic profile, bleeding patterns, and available products.
5. A.Gringeri, B.Ewenstein, A.Reininger. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia. 2014;20:459–463.
6. A.Nijdam, K.Kurnik, R.Liesner, et al. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. Haemophilia. 2015;21:444–450.
7. I.M.Nilsson, E.Berntorp, T.Lofqvist, et al. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232:25–32.
8. M.B.Funk, H.Schmidt, S.Becker, et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia. 2002;8:98–103.
9. K.Fischer. Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus. 2012;10:169–173.
10. K.Fischer, J.Astermark, J.G.van der Bom, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia. 2002;8:753–760.
11. M.J.Manco-Johnson, T.C.Abshire, A.D.Shapiro, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544.
12. J.Kraft, V.Blanchette, P.Babyn, et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia a treated with tailored primary prophylaxis in Canada. J Thromb Haemost. 2012;10:2494–2502.
13. M.Funk, H.Schmidt, C.Escuriola-Ettingshausen, et al. Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis. Ann Hematol. 1998;77:171–174.
14. I.E.M.den Uijl, A.M.A.de Schepper, M.Camerlinck, et al. Magnetic resonance imaging in teenagers and young adults with limited haemophilic arthropathy: baseline results from a prospective study. Haemophilia. 2011;17:926–930.
15. B.Sørensen, G.Auerswald, G.Benson, et al. Rationale for individualizing haemophilia care. Blood Coagul Fibrinolysis. 2015;26:849–857.
16. M.C.Ar, I.Vaide, E.Berntorp, et al. Methods for individualising factor VIII dosing in prophylaxis. Eur J Haematol. 2014;93(Suppl 76):16–20.
17. L.A.Valentino. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20:607–615.
18. M.McCarthy. Obama seeks $213m to fund “precision medicine”. BMJ. 2015;350:h587.
19. A.G.Awad. ‘The patient’: at the center of patient-reported outcomes. Expert Rev Pharmacoecon Outcomes Res. 2015;15:729–731.•• This paper highlights the importance of patient’s involvement in any treatment regimen, as it is the patient’s perceived well-being that determines whether or not an outcome was positive or not. This implies shared responsibility in adhering to treatment regimens, which could lead to improved outcomes and cost containment.
20. S.R.Earnshaw, C.N.Graham, C.L.McDade, et al. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015;21:310–319.
21. M.A.Escobar. Health economics in haemophilia: a review from the clinician’s perspective. Haemophilia. 2010;16(Suppl 3):29–34.
22. N.Risebrough, P.Oh, V.Blanchette, et al. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia. 2008 Jul;14(4):743–752.
23. A.Farrugia, J.Cassar, M.C.Kimber, et al. Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia. 2013;19:e228–e238.
24. E.J.Neufeld, M.Recht, H.Sabio, et al. Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. Value Health. 2012;15:916–925.
25. M.Valente, P.A.Cortesi, G.Lassandro, et al. Health economic models in hemophilia A and utility assumptions from a clinician’s perspective. Pediatr Blood Cancer. 2015;62:1826–1831.• The importance of key stakeholder cooperation in hemophilia treatment is highlighted as a means of ensuring the utility and improved quality of life of prophylactic or on-demand treatment of hemophilia A.
26. M.W.Skinner. WFH: closing the global gap - achieving optimal care. Haemophilia. 2012;18(Suppl 4):1–12.
27. B.Unim, M.A.Veneziano, A.Boccia, et al. Pharmacoeconomic review of prophylaxis treatment versus on-demand. ScientificWorldJournal. 2015;2015:596164.
28. United Kingdom Haemophilia Centre Director’s Organisation. Bleeding disorder statistics for April 2011 to March 2012: a report from the Natinal Haemohilia Database. Vol. 87. United Kingdom Haemophilia Centre Director’s Organisation (UKHCDO); 2012. Available from: http://www.ukhcdo.org/docs/AnnualReports/2012/1UK%20National%20Haemophilia%20Database%20Bleeding%20Disorder%20Statistics%202011-2012%20for%20website.pdf
29. L.A.Valentino, V.Mamonov, A.Hellmann, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10:359–367.
30. M.J.Manco-Johnson, C.L.Kempton, M.T.Reding, et al. Randomized, controlled, parallel-group trial of routine prophylaxis versus on-demand treatment with rFVIII-FS in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013;11:1119–1127.
31. U.Schneider. Double moral hazard and outcome-based remuneration of physicians. Working Paper 022. Bavarian Graduate Program in Econmoics (BGPE); 2007. Available from: http://www.bgpe.de/texte/DP/022_schneider.pdf
32. M.Carlsson, E.Berntorp, S.Björkman, et al. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia. 1997;3:96–101.•• This was one of the first studies demonstrating the importance of individual pharmacokinetic dosing of factor concentrates in achieving optimum results in patient outcomes, without necessarily using larger amounts of expensive clotting factors.
33. S.A.Brown, J.Phillips, C.Barnes, et al. Challenges in haemophilia care in Australia and New Zealand. Curr Med Res Opin. 2015;31:1985–1991.
34. S.V.Antunes, S.Tangada, J.Phillips, et al. Comparison of historic on-demand and prophylaxis bleeding episodes in hemophilia A and B patients with inhibitors treated with FEIBA NF. Haemophilia. 2014;20(Suppl 3):96.
35. E.Berntorp, G.Spotts, L.Patrone, et al. Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biologics. 2014;2014:115–127.
36. H.Pollmann, R.Klamroth, N.Vidovic, et al. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study. Ann Hematol. 2013;92:689–698.
37. M.Khawaji, J.Astermark, E.Berntorp. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol. 2012;88:329–335.
38. A.Gringeri, B.Lundin, S.Von Mackensen, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9:700–710.
39. P.Petrini, L.A.Valentino, A.Gringeri, et al. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015;8:237–246.
40. J.Ahnström, E.Berntorp, K.Lindvall, et al. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia. 2004;10:689–697.
41. S.Fernandes, M.Carvalho, M.Lopes, et al. Impact of an individualized prophylaxis approach on young adults with severe hemophilia. Semin Thromb Hemost. 2014;40:785–789.
42. T.Abshire. An approach to target joint bleeding in hemophilia: prophylaxis for all or individualized treatment? J Pediatr. 2004;145:581–583.
43. C.R.Broderick, R.D.Herbert, J.Latimer, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012;308:1452–1459.
44. B.O’Mahony, A.Kent, S.Ayme. Pfizer-sponsored satellite symposium at the European Haemophilia Consortium (EHC) congress: changing the policy landscape: haemophilia patient involvement in healthcare decision-making Pfizer-sponsored satellite symposium at the European Haemophilia Consortium (EHC) congress: changing the policy landscape: haemophilia patient involvement in healthcare decision-making. Eur J Haematol. 2014;92(Suppl 74):1–8.
45. S.E.Croteau, M.Padula, K.Quint, et al. Center-based quality initiative targets youth preparedness for medical independence: HEMO-milestones tool in a comprehensive hemophilia clinic setting. Pediatr Blood Cancer. 2016 Mar;63(3):499–503.
46. A.J.Reininger, H.E.Chehadeh. The principles of PK-tailored prophylaxis. Hamostaseologie. 2013;33(Suppl 1):S32–S35.• This paper describes the methodology of using pharmacokinetic-guided prophylaxis to optimize clinical outcomes in patients, and stresses the need to consider individual patients’ treatment preferences in order to maximize treatment utility.
47. P.W.Collins. Personalized prophylaxis. Haemophilia. 2012;18(Suppl 4):131–135.
48. P.W.Collins, S.Björkman, K.Fischer, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8:269–275.
49. A.H.Miners. Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much? Haemophilia. 2013;19:174–180.
50. A.Coppola, M.Morfini, E.Cimino, et al. Current and evolving features in the clinical management of haemophilia. Blood Transfus. 2014;12(Suppl 3):S554–S562.
51. D.U.Iem, K.Fischer, S.Halimeh, et al. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis. Thromb Haemost. 2008;99:965–968.
52. A.Gringeri, P.Cortesi, S.Iannazzo, et al. PK-driven prophylaxis using MyPKFiT vs. standard prophylaxis in haemophilia A: a cost-effectiveness analysis. Poster: presented at (EAHAD); 2016 February 3–5; Malmö, Sweden.
53. S.Geraghty, T.Dunkley, C.Harrington, et al. Practice patterns in haemophilia A therapy – global progress towards optimal care. Haemophilia. 2006;12:75–81.
54. N.A.Duncan, W.G.Kronenberger, S.Krishnan, et al. Adherence to prophylactic treatment in hemophilia as measured using thre VERITAS-Pro and annual bleed rate (ABR). Value Health. 2014;17(3):A230.
55. P.W.Collins, V.S.Blanchette, K.Fischer, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost. 2009;7:413–420.
56. P.Petrini, A.Seuser. Haemophilia care in adolescents–compliance and lifestyle issues. Haemophilia. 2009;15(Suppl 1):15–19.
57. S.Zappa, M.McDaniel, J.Marandola, et al. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia. 2012;18:e140–e153.• This is an example of how benchmarking can support treatment regimen development; it shows, for example, which patient groups tend to have the highest mortality rates, and how their treatment could potentially be improved.
58. D.Quon, M.Reding, C.Guelcher, et al. Unmet needs in the transition to adulthood: 18- to 30-year-old people with hemophilia. Am J Hematol. 2015;90(Suppl 2):S17–S22.
59. B.O’Mahony, M.W.Skinner, D.Noone, et al. Assessments of outcome in haemophilia - a patient perspective. Haemophilia. 2016 Mar 14. doi:10.1111/hae.12922. [Epub ahead of print]
60. C.R.M.Hay. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia. 2013;19:660–667.
61. J.Oldenburg, K.Kurnik, A.Huth-Kuhne, et al. AHEAD. Advate in HaEmophilia A outcome database. Hamostaseologie. 2010;30:S23–S25.
62. A.Iorio, M.Marcucci, J.Cheng, et al. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM. Haemophilia. 2014;20:777–783.
63. R.Klamroth, H.Pollmann, C.Hermans, et al. The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study. Haemophilia. 2011;17:412–421.
64. M.Richards, C.Altisent, A.Batorova, et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia. 2007;13:473–479.
65. P.W.Collins, K.Fischer, M.Morfini, et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17:2–10.
66. B.M.Feldman, K.Berger, R.Bohn, et al. Haemophilia prophylaxis: how can we justify the costs? Haemophilia. 2012;18:680–684.
67. K.Fischer, M.E.Pouw, D.Lewandowski, et al. A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. Haematologica. 2011;96:738–743.
68. P.De Moerloose, D.Arnberg, B.O’Mahony, et al. Improving haemophilia patient care through sharing best practice. Eur J Haematol. 2015;95(Suppl 79):1–8.
69. A.Nijdam, M.Bladen, N.Hubert, et al. Using routine haemophilia joint health score for international comparisons of haemophilia outcome: standardization is needed. Haemophilia. 2016;22(1):142–147. doi:10.1111/hae.12755.
70. A.S.Kesselheim, J.J.Gagne. Strategies for postmarketing surveillance of drugs for rare diseases. Clin Pharmacol Ther. 2014;95:265–268.
71. L.B.Amerine, S.L.Chen, R.Daniels, et al. Impact of an innovative blood factor stewardship program on drug expense and patient care. Am J Health Syst Pharm. 2015 Sep 15;72(18):1579–1584.•• A stewardship program was initiated at the University of North Carolina Medical Center to coordinate treatment of hemophilia patients between pharmacists, hematologists, and patients to facilitate optimum dosing and outcomes and controlled costs. This pilot program was extremely successful and resulted in significant savings while reducing bleeding episodes in these patients (i.e. improving outcomes).
72. J.Concato, E.V.Lawler, R.A.Lew, et al. Observational methods in comparative effectiveness research. Am J Med. 2010;123:e16–e23.
73. R.Lassila, C.Rothschild, P.De Moerloose, et al. The European haemophilia therapy standardisation board. Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders. Haemophilia. 2005;11:353–359.
74. S.C.Darby, S.W.Kan, R.J.Spooner, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110:815–825.
75. M.E.Mingot-Castellano, L.González-Diaz, R.Tamayo-Bermejo, et al. Adult severe haemophilia A patients under long-term prophylaxis with factor VIII in routine clinical practice. Blood Coagul Fibrinolysis. 2015 Jul;26(5):509–514.
76. S.Björkman, V.S.Blanchette, K.Fischer, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010;8:730–736.
77. S.Burock, F.Meunier, D.Lacombe. How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment? Eur J Cancer. 2013 Sep;49(13):2777–2783.
78. Health Affairs Blog. 2015. [cited 2016 Apr11]. Available from: http://healthaffairs.org/blog/2015/04/28/its-time-for-value-based-payment-in-oncology/.
79. N.S.Bardach, J.J.Wang, S.F.De Leon, et al. Effect of pay-for-performance incentives on quality of care in small practices with electronic health records: a randomized trial. JAMA. 2013;310(10):1051–1059.
80. A.K.Jha, K.E.Joynt, J.E.Orav, et al. The long-term effect of premier pay for performance on patient outcomes. N Engl J Med. 2012 Apr 26;366:1606–1615.